SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE M impact

CHMP maintains negative opinion on MaaT Pharma’s MaaT013

MaaT Pharma said the CHMP upheld its negative opinion on the CMA for MaaT013 (Xervyteg®) after re-examination.

MAAT

MaaT Pharma said the CHMP maintained its negative opinion on the CMA for MaaT013 (Xervyteg®) after re-examination. The company plans to focus on the PHOENIX randomized Phase 3 trial, subject to funding and regulatory clearance; FDA Type C feedback supports it as registrational.Material DetailsConte…

Related stories